首页|血清血管内皮生长因子及肿瘤标志物水平与肺癌患者临床分期的关系

血清血管内皮生长因子及肿瘤标志物水平与肺癌患者临床分期的关系

Relationship between serum levels of vascular endothelial growth factor,tumor markers and clinical staging of lung cancer

扫码查看
目的 探讨血清血管内皮生长因子(VEGF)及肿瘤标志物[癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、鳞状细胞癌抗原(SCC-Ag)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)]水平与肺癌患者临床分期的关系.方法 选取112例肺癌患者作为观察组,87例健康体检者作为对照组,比较两组受试者、不同临床分期肺癌患者血清VEGF、CEA、NSE、SCC-Ag、CYFRA21-1水平.相关性分析采用Spearman分析;绘制受试者工作特征(ROC)曲线,计算曲线下面积(AUC),评估VEGF、CEA、NSE、SCC-Ag、CYFRA21-1单独及联合检测对肺癌患者临床分期的诊断效能.结果 观察组患者血清VEGF、CEA、NSE、SCC-Ag、CYFRA21-1水平均明显高于对照组,差异均有统计学意义(P<0.01).Ⅲ~Ⅳ期肺癌患者血清VEGF、CEA、NSE、SCC-Ag、CYFRA21-1水平均明显高于Ⅰ~Ⅱ期患者,差异均有统计学意义(P<0.01).ROC曲线显示,VEGF、CEA、NSE、SCC-Ag、CYFRA21-1联合检测诊断肺癌患者临床分期的AUC为0.952(95%CI:0.915~0.989),均高于各指标单独检测,此时的灵敏度为0.862,特异度为0.926.血清VEGF、CEA、NSE、SCC-Ag、CYFRA21-1与肺癌患者的临床分期均呈正相关(P<0.05).结论 肺癌患者血清VEGF、CEA、NSE、SCC-Ag、CYFRA21-1水平均明显升高,各指标联合检测对肺癌患者的临床分期有较高的诊断价值,且与临床分期均呈正相关.
Objective To explore the relationship between serum levels of vascular endothelial growth factor(VEGF),tumor markers[carcinoembryonic antigen(CEA),neuron specific enolase(NSE),squamous cell carcinoma anti-gen(SCC-Ag),cyto-keratin 19 fragment antigen 21-1(CYFRA21-1)]and clinical staging of lung cancer.Method A to-tal of 112 lung cancer patients were selected as the observation group,and 87 healthy individuals were selected as the con-trol group.The serum levels of VEGF,CEA,NSE,SCC-Ag,and CYFRA21-1 were compared between the two groups of subjects and lung cancer patients with different clinical stages.Correlation analysis was conducted by Spearman analysis;the receiver operating characteristic(ROC)curve was drawn,the area under the curve(AUC)was calculated,and the val-ue of VEGF,CEA,NSE,SCC-Ag,and CYFRA21-1 single and combined detection in diagnosing clinical staging of lung cancer were evaluated.Result The serum levels of VEGF,CEA,NSE,SCC-Ag,and CYFRA21-1 in the observation group were significantly higher than those in the control group,and the differences were statistically significant(P<0.01).The serum levels of VEGF,CEA,NSE,SCC-Ag,and CYFRA21-1 in stage Ⅲ-Ⅳ of lung cancer patients were significant-ly higher than those in stage Ⅰ-Ⅱ,and the differences were statistically significant(P<0.01).The ROC curve showed that the AUC of VEGF,CEA,NSE,SCC-Ag,and CYFRA21-1 combined detection in diagnosing clinical staging of lung can-cer was 0.952(95%CI:0.915-0.989),which was higher than those of single detection of each indicator.At this time,the sensitivity was 0.862 and the specificity was 0.926.Serum VEGF,CEA,NSE,SCC-Ag,CYFRA21-1 were positively cor-related with the clinical staging of lung cancer patients(P<0.05).Conclusion The levels of serum VEGF,CEA,NSE,SCC-Ag,and CYFRA21-1 in lung cancer patients are significantly elevated.These indicators combined detection has high diagnostic value for the clinical staging of lung cancer patients,and these indicators are positively correlated with clinical staging.

vascular endothelial growth factorcarcinoembryonic antigenneuron specific enolasesquamous cell carcinoma antigencyto-keratin 19 fragment antigen 21-1lung cancer

刘胜泉、史冬冬、杨林

展开 >

濮阳油田总医院医学检验科,河南 濮阳 457001

血管内皮生长因子 癌胚抗原 神经元特异性烯醇化酶 鳞状细胞癌抗原 细胞角质蛋白19片段抗原21-1 肺癌

2024

癌症进展
中国医学科学院,北京协和医学院

癌症进展

影响因子:1.004
ISSN:1672-1535
年,卷(期):2024.22(14)